모더나

주관 임상 단계 분포

• 정책이벤트2026-07-15

  사노피, 화이자·모더나 상대로 mRNA 특허 소송 새 국면 열어

  사노피가 화이자와 모더나의 코로나19 mRNA 백신에 대해 특허 침해 소송을 새롭게 제기했다. 화이자와 모더나는 각각 별도로 진행되던 mRNA 특허 소송에서 일부 사안을 정리한 상태였으나, 사노피가 이번에 새로운 소송 전선을 열면서 양사의 블록버스터 백신을 둘러싼 특허 분쟁이 재점화됐다. 구체적인 소송 청구 금액이나 쟁점이 된 특허 세부 내용은 기사에 명시되지 않았다.

  Fierce Pharma ↗

진행 중인 임상

• 3상모집 중협력· Non-small Cell Lung Cancer

  A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

  NCT07513376
• 2상모집 중· Lyme Disease

  A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)

  NCT07561294
• 3상모집 중· Influenza

  A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults

  NCT07496450
• 1상모집 중· Epstein-Barr Virus

  A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age

  NCT07478952
• 1상모집 중단 (진행 중)협력· HIV Infections

  Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall Good Health in South Africa.

  NCT06694753
• 2상모집 중협력· Squamous Non-small Cell Lung Cancer

  A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

  NCT07221474
• 4상모집 중단 (진행 중)협력· COVID-19

  Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19

  NCT07279766
• 4상모집 중단 (진행 중)· SARS-CoV-2

  A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

  NCT07266558
• 1/2상모집 중· Relapsed or Refractory Multiple Myeloma

  A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07116616
• 1상모집 중협력· Cutaneous Melanoma

  ACTengine® IMA203 Combined With mRNA-4203

  NCT06946225
• 2상모집 중· Multiple Sclerosis

  A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

  NCT06735248
• 1상모집 중단 (진행 중)· Advanced Solid Tumors

  A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors

  NCT06880549
• 2상모집 중협력· Urinary Bladder Neoplasms

  A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

  NCT06833073
• 1상모집 중단 (진행 중)· Healthy Participants

  A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants

  NCT06655870
• 3상모집 중협력· Carcinoma, Non-Small-Cell Lung

  A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

  NCT06623422
• 3상모집 중단 (진행 중)· Acute Gastroenteritis

  A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis

  NCT06592794
• 4상모집 중· SARS-CoV-2

  A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

  NCT06585241
• 2상모집 중단 (진행 중)협력· Renal Cell Carcinoma

  A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

  NCT06307431
• 1/2상모집 중단 (진행 중)협력· Bladder Cancer

  A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

  NCT06305767
• 3상모집 중협력· Non-small Cell Lung Cancer

  A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

  NCT06077760